Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR55 CEUS for Pancreatic Lesions
NCT03486327Phase 2Terminated
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of perfluorobutane/nitrogen lipopeptide-coated microbubbles in pancreatic ductal adenocarcinoma (PDAC), sponsored by Bracco Diagnostics Inc.. Started Jul 2018; status: terminated.
02
Drugs
perfluorobutane/nitrogen lipopeptide-coated microbubbles
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03486327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486327.